Specifically, we compared the capacity of Oncotype DX, developed exclusively on and for LN negative (LN-) ER+ patients [17], and Prosigna, developed on all clinical subtypes of breast cancer including those with and without lymph involvement [18], for their capacity to predict outcome in patients with ER+/LN- and ER+/LN+ tumours. Here, ESR1 is linked to neoplasm.